Kyverna Therapeutics(US:KYTX) Prnewswireยท2025-01-24 10:45Core Viewpoint - A class action securities lawsuit has been filed against Kyverna Therapeutics, Inc. due to alleged securities fraud affecting investors who purchased shares during the company's February 2024 initial public offering [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors adversely affected by alleged securities fraud related to Kyverna Therapeutics, Inc. [2] - The complaint alleges that false statements and omissions were made regarding the IPO strategy, terms, and disclosures in the Offering Documents [3]. - The underwriter defendants are accused of being aware of Kyverna's undisclosed issues due to constant communications with the company's management and legal representatives [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant time frame have until February 7, 2025, to request appointment as lead plaintiff [4]. - Participation in the lawsuit does not require any out-of-pocket costs or fees for class members [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [5]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [5].